Skip to content
Rio de Janeiro · São Paulo · Salvador — matters across Brazil
Bruno Marcelos — Escritório de Advocacia

Pauta Regulatória · Daily brief

No. 210

Automatically translated from the Portuguese edition, which prevails in case of discrepancy. Ler em português

Federal Official Gazette

No updates.

ANS news

ANS holds 54th Technical Meeting of Cosaúde

The meeting will take place on Aug 25. See the schedule

August 25, 2026

9 a.m. – Discussion of proposals for inclusion in the List of Health Procedures and Events (Rol) concerning the following technologies:

SHIFT

TECHNOLOGY

INDICATION FOR USE

9 a.m. to 12:30 p.m.

UAT 209 – 21-gene test for genomic expression profiling of breast tumors

(Preliminary discussion)

Support for therapeutic decision-making for patients with early-stage breast cancer (stages I, II and IIIA), hormone receptor-positive (HR+), human epidermal growth factor receptor type 2-negative (HER2-), with node-negative disease or node-positive disease involving one to three lymph nodes.

UAT 184 – Amendment of DUT 110.39 – Molecular DNA analysis

(Continuation of preliminary discussion)

Diagnosis of patients with intellectual disability of undetermined cause.

2 p.m. to 6 p.m.

UAT 202 – Update of DUT 52 – Digital mammography (internal demand)

(Analysis of contributions from social participation)

Screening, diagnosis and treatment follow-up of breast cancer.

UAT 205 – Implantation of a cardiac contractility modulation device

(Preliminary discussion)

Treatment of patients with symptomatic chronic heart failure (NYHA III–IV), refractory to optimized pharmacological treatment, with ejection fraction between 25% and 45%, QRS complex <130 ms, and with no indication for cardiac resynchronization therapy.

Open public consultations

  • CP 175. Subject: criticisms and suggestions regarding the preliminary recommendations against incorporating the technologies covered by UAT No. 199 – Cholangioscopy, UAT No. 200 – Next-generation sequencing (NGS) panel and UAT No. 206 – Tepotinib hydrochloride. Deadline: Aug 12, 2026 to Aug 31, 2026

Scheduled public hearings

  • AP 68. Subject: preliminary recommendation against incorporating the technologies covered by UAT No. 199 – Cholangioscopy, UAT No. 200 – Next-generation sequencing (NGS) panel and UAT No. 206 – Tepotinib hydrochloride. Date: August 20, 2026, from 9 a.m. to 1 p.m., virtually, via the Microsoft Teams platform.

Open public calls for input

There is no open public call for input.

Open public calls

Discount cards, prepaid cards, or related services. Deadline: From Jun 2, 2026 to Aug 18, 2026.

Other news

‘Our market is complementary to that of health plans,’ says CEO of Dr. Consulta

Source: oglobo.globo.com · read the full article

Gilmar Mendes overturns decision that required coverage of automatic insulin pump

Source: jota.info · read the full article

Sources: Federal Official Gazette (DOU) and the ANS website. Press items link to the original article. This brief is for information only and does not constitute legal advice.